JY
SYRE icon

Jeff Yass’s Spyre Therapeutics SYRE Stock Holding History

Jeff Yass’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.49M Buy
39,311
+10,349
+36% +$755K ﹤0.01% 5321
2026
Q1 		$1.46M Buy
28,962
+22,851
+374% +$861K ﹤0.01% 6960
2025
Q4 		$200K Buy
+6,111
New +$160K ﹤0.01% 10878
2025
Q3 		– Sell
-59,816
Closed -$895K – 13836
2025
Q2 		$895K Buy
59,816
+1,120
+2% +$16.6K ﹤0.01% 7714
2025
Q1 		$947K Buy
58,696
+35,607
+154% +$741K ﹤0.01% 7391
2024
Q4 		$538K Buy
23,089
+9,891
+75% +$290K ﹤0.01% 8501
2024
Q3 		$388K Buy
+13,198
New +$368K ﹤0.01% 9056
2024
Q2 		– Sell
-101,503
Closed -$3.85M – 13210
2024
Q1 		$3.85M Buy
+101,503
New +$2.94M ﹤0.01% 4068
2023
Q3 		– Sell
-1,447
Closed -$16.3K – 12950
2023
Q2 		$16.3K Buy
+1,447
New +$6.86K ﹤0.01% 11677
2023
Q1 		– Sell
-2,038
Closed -$22.9K – 13478
2022
Q4 		$22.9K Buy
+2,038
New +$36.6K ﹤0.01% 11715
2022
Q3 		– Sell
-2,608
Closed -$33K – 14101
2022
Q2 		$33K Buy
+2,608
New +$91.4K ﹤0.01% 12178
2021
Q4 		– Sell
-448
Closed -$89K – 13891
2021
Q3 		$89K Buy
+448
New +$78.4K ﹤0.01% 12128
2021
Q1 		– Sell
-426
Closed -$84K – 12836
2020
Q4 		$84K Sell
426
-23
-5% -$4.77K ﹤0.01% 10580
2020
Q3 		$80K Buy
+449
New +$83.1K ﹤0.01% 10038
2020
Q2 		– Sell
-601
Closed -$70K – 10902
2020
Q1 		$70K Buy
+601
New +$102K ﹤0.01% 9521
2019
Q4 		– Sell
-625
Closed -$120K – 10612
2019
Q3 		$120K Buy
625
+142
+29% +$27.7K ﹤0.01% 9464
2019
Q2 		$83K Buy
+483
New +$83.5K ﹤0.01% 9687
2017
Q3 		– Sell
-6,800
Closed -$653K – 9605
2017
Q2 		$653K Buy
+6,800
New +$940K ﹤0.01% 6123

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jeff Yass's SYRE Position: Q2 2026 in Review

Jeff Yass increased its Spyre Therapeutics (SYRE) stake by 36% in Q2 2026, buying an estimated $755K and bringing the position to 39,311 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #5321.

Jeff Yass first reported a position in SYRE in Q2 2017 and has held it in 18 quarters since. The position peaked at $3.85M in Q1 2024. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Jeff Yass held 39,311 shares of Spyre Therapeutics worth $3.49M as of Q2 2026.
  • Jeff Yass bought 10,349 Spyre Therapeutics shares in Q2 2026, an estimated $755K.
  • Spyre Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5321 holding.
  • Jeff Yass first reported a position in Spyre Therapeutics in Q2 2017 and has held it in 18 quarters since.
  • Jeff Yass's Spyre Therapeutics position peaked at $3.85M in Q1 2024.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.